Low Breast Cancer

• CLINICAL_TRIALS trial_result · 2026-02-13
  Clinical Trial Update: ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer [Phase 2]

  A Phase 2 trial evaluating ARX788 for HER2-low breast cancer (locally advanced unresectable or metastatic) is currently not yet recruiting.

• CLINICAL_TRIALS trial_result · 2026-01-30
  Clinical Trial Update: Neoadjuvant Pyrotinib in HR-positive and HER2-low High-risk Early Breast Cancer [Phase 3]

  A Phase 3 trial update reports on neoadjuvant Pyrotinib for hormone-receptor-positive, HER2-low high-risk early breast cancer, with the tria…

• CLINICAL_TRIALS trial_result · 2025-08-07
  Clinical Trial Update: Efficacy and Safety of T-DXd in Patients With HER2-positive and HER2-low Metastatic Breast Cancer: a Real-world Study

  This real-world study updates the efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients with HER2-positive and HER2-low metastat…

• CLINICAL_TRIALS trial_result · 2024-12-13
  Clinical Trial Update: A Study Evaluating the Efficacy and Safety of De Trastuzumab (T-DXd) in Combination with Immunotherapy for the Neoadjuvant Treatment of HR-positive HER2 Low-expressing Chinese Patients with Early-stage Breast Cancer [Phase 2]

  Phase 2 clinical trial evaluating trastuzumab deruxtecan in combination with immunotherapy as neoadjuvant treatment for HR-positive, HER2-lo…

• CLINICAL_TRIALS trial_result · 2024-11-07
  Clinical Trial Update: An Observational Study of Patients Receiving T-DXd for Treatment of HER2+, and HER2-low Unresectable and/or Metastatic Breast Cancer

  Observational study of patients treated with trastuzumab deruxtecan (Enhertu) for HER2-positive and HER2-low unresectable/metastatic breast …

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.